Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 117Myelodysplastic Syndromes 73Leukemia, Myelomonocytic, Chronic 34Leukemia 30Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myelomonocytic, Acute 8Congenital Abnormalities 8Recurrence 7Multiple Myeloma 7Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6Primary Myelofibrosis 5Lung Neoplasms 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Prostatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Melanoma 4Lymphoma, Follicular 4Pancreatic Neoplasms 3

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Azacitidine × Clear all
NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
58 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡